CardiaTec Biosciences
CardiaTec builds the largest human cardiac tissue multi‑omicsdatabase by collecting genomics, epigenomics, transcriptomics, and proteomics data from a network of hospitals. It applies advanced computational modeling to analyze this high‑dimensional data and uncover disease mechanisms driving cardiovascular pathology. The platform enables the discovery and development of novel therapeutics targeting cardiovascular diseases.
Traction 7/10Founded 2021
Cambridge, United Kingdom · HQ
- Biotechnology
Updated 12 days ago
Funding
Raised to date
$8.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
CECGLSOV$6.5M · Seed
Announced Sep 2024 · from article date
Disclosed cumulative: $8.3M
2/2
RoundDateAmountValuationInvestors
Founders
Founder details are not available yet.
Product
Features
- CardiaTec utilizes large-scale multiomics data, including genomics, transcriptomics, proteomics, and epigenomics, to construct a comprehensive human cardiac tissue database aimed at discovering novel therapeutics for cardiovascular diseases. The company addresses the critical gap in understanding the complex biology of cardiovascular conditions, which has hindered effective clinical translation and investment in this area.